论文部分内容阅读
目的探讨参松养心胶囊联合环磷酸腺苷葡甲胺治疗缓慢性心律失常合并期前收缩及快速心律失常的临床疗效。方法选择2013年1月—2015年12月芜湖市镜湖医院收治的缓慢性心律失常合并期前收缩及快速心律失常患者84例,随机分为对照组40例和观察组44例。对照组患者进行为期1个月的常规药物治疗;观察组患者在常规药物治疗的基础上口服参松养心胶囊1个月,同时静脉滴注环磷腺苷葡甲胺1周。比较两组的临床抗心律失常疗效和抗心动过缓疗效。结果观察组患者的临床抗心律失常疗效和抗心动过缓疗效均优于对照组(P<0.05)。结论参松养心胶囊联合环磷腺苷葡甲胺治疗缓慢性心律失常合并期前收缩及快速心律失常的临床疗效确切。
Objective To investigate the clinical effects of Shensong Yangxin Capsule combined with cyclic adenosine monophosphate megacylamine in the treatment of systolic and tachyarrhythmia complicated with chronic arrhythmia. Methods From January 2013 to December 2015, 84 patients with systolic and tachyarrhythmia and chronic arrhythmia admitted to Jinghu Hospital of Wuhu City were randomly divided into control group (n = 40) and observation group (n = 44). Patients in the control group received routine medical treatment for one month. Patients in the observation group received oral Shensong Yangxin Capsule for 1 month on the basis of conventional medical treatment, while intravenous injection of cyclic adenosine monophosphate (AMI) for 1 week. The clinical antiarrhythmic efficacy and anti-bradycardia efficacy were compared between the two groups. Results The clinical efficacy of anti-arrhythmia and anti-bradycardia in observation group were better than those in control group (P <0.05). Conclusion Shensong Yangxin Capsule combined with cyclic adenosine monophosphate meglumine hydrochloride in the treatment of patients with chronic arrhythmia with premature systole and tachyarrhythmia has definite curative effect.